QuidelOrtho, Lifotronic Technology to Expand Global Immunoassay Portfolio

QuidelOrtho has forged a long-term strategic supply agreement with Lifotronic Technology Co. Ltd. to expand its global immunoassay portfolio and accelerate customer access to scalable, high-quality, cost-efficient solutions across select markets outside the United States.

The agreement provides QuidelOrtho access to multiple high-throughput and low-to-mid volume immunoassay analyzer platforms, each supported by a broad menu of assays spanning routine and specialty testing. The collaboration is expected to expand QuidelOrtho’s immunoassay menu with more than 25 new assays on these systems that are not currently available on the VITROS system, within a total menu of more than 70 assays on these new partner platforms.

“Through our collaboration with Lifotronic Technology, QuidelOrtho will rapidly introduce scalable testing solutions that further advance our long-term innovation strategy in core growth markets,” said Bryan Hanson, senior vice president of Global Clinical Laboratory and Transfusion Medicine at QuidelOrtho. “This agreement strengthens our portfolio in markets where assay breadth and cost efficiency are key requirements, while offering customers a broader and more diverse set of solutions.”

These additions are planned to increase QuidelOrtho’s ability to compete for full-menu tenders and serve a wider range of laboratory settings, from smaller laboratories seeking low-volume solutions to larger, high-throughput environments that require scalable capacity and broad test menus.

The commercial focus will be on Europe, the Middle East, Africa, Mexico, Central America, South America, India, China, Japan, and the Asia-Pacific regions. This strategic expansion is planned to support QuidelOrtho’s ability to address menu gaps, increase competitiveness in international tenders, and deliver more complete immunoassay solutions to laboratories seeking broader menus and flexible system options.

“This strategic partnership with QuidelOrtho marks an important milestone in Lifotronic Technology’s global expansion strategy,” Lifotronic Technology Chairman Liu Xiancheng, stated. “Going forward, we will work closely with QuidelOrtho, continuing to leverage our in-house R&D strengths to deliver high-value diagnostic solutions that meet real clinical needs for customers worldwide.”

QuidelOrtho is a global developer of diagnostic solutions, with expertise in clinical chemistry, immunoassay, immunohematology, and molecular diagnostics. The company delivers fast, accurate, and reliable test results to help improve patient outcomes across settings ranging from point-of-care to hospitals, laboratories, and clinics. QuidelOrtho partners with healthcare providers to advance diagnostic technologies, connecting insights with solutions to enable informed decision-making and better healthcare delivery.

Shenzhen Lifotronic Technology Co. Ltd. is a high-tech medical device company driven by both R&D and commercialization, that focuses on in-vitro diagnostics and therapy/rehabilitation. In the IVD field, Lifotronic Technology has developed products covering electrochemiluminescence, HbA1c, and specific protein technologies. In electrochemiluminescence, the company has achieved a full lineup of low-, mid-, and high-throughput immunoassay instruments and reagents. Its products have obtained international certifications such as CE and are distributed globally.